全文获取类型
收费全文 | 89572篇 |
免费 | 8104篇 |
国内免费 | 5955篇 |
专业分类
耳鼻咽喉 | 746篇 |
儿科学 | 1164篇 |
妇产科学 | 958篇 |
基础医学 | 8303篇 |
口腔科学 | 1673篇 |
临床医学 | 12294篇 |
内科学 | 11311篇 |
皮肤病学 | 1008篇 |
神经病学 | 3277篇 |
特种医学 | 3107篇 |
外国民族医学 | 30篇 |
外科学 | 8125篇 |
综合类 | 18952篇 |
现状与发展 | 25篇 |
一般理论 | 4篇 |
预防医学 | 7878篇 |
眼科学 | 1801篇 |
药学 | 10280篇 |
110篇 | |
中国医学 | 6213篇 |
肿瘤学 | 6372篇 |
出版年
2024年 | 281篇 |
2023年 | 989篇 |
2022年 | 2626篇 |
2021年 | 3307篇 |
2020年 | 2718篇 |
2019年 | 2256篇 |
2018年 | 2268篇 |
2017年 | 2543篇 |
2016年 | 2268篇 |
2015年 | 3694篇 |
2014年 | 4705篇 |
2013年 | 4769篇 |
2012年 | 7074篇 |
2011年 | 7796篇 |
2010年 | 6084篇 |
2009年 | 5382篇 |
2008年 | 5934篇 |
2007年 | 6008篇 |
2006年 | 5671篇 |
2005年 | 5065篇 |
2004年 | 3762篇 |
2003年 | 3464篇 |
2002年 | 2906篇 |
2001年 | 2283篇 |
2000年 | 1924篇 |
1999年 | 1583篇 |
1998年 | 937篇 |
1997年 | 1005篇 |
1996年 | 679篇 |
1995年 | 589篇 |
1994年 | 530篇 |
1993年 | 355篇 |
1992年 | 358篇 |
1991年 | 316篇 |
1990年 | 275篇 |
1989年 | 216篇 |
1988年 | 183篇 |
1987年 | 188篇 |
1986年 | 153篇 |
1985年 | 99篇 |
1984年 | 56篇 |
1983年 | 33篇 |
1982年 | 23篇 |
1981年 | 21篇 |
1980年 | 28篇 |
1979年 | 48篇 |
1978年 | 24篇 |
1976年 | 13篇 |
1975年 | 18篇 |
1974年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
2.
Noninvasive imaging of cardiac fibrosis is important for early diagnosis and intervention in chronic heart diseases. Here, we investigated whether noninvasive, contrast agent-free MRI T2-mapping can quantify myocardial fibrosis in preclinical models of aging and pressure overload. Myocardial fibrosis and remodeling were analyzed in two animal models: (i) aging (15-month-old male CF-1 mice vs. young 6- to 8-week-old mice), and (ii) pressure overload (PO; by transverse aortic constriction in 4- to 5-month-old male C57BL/6 mice vs. sham-operated for 14 days). In vivo T2-mapping was performed by acquiring data during the isovolumic and early diastolic phases, with a modified respiratory and ECG-triggered multiecho TurboRARE sequence on a 7-T MRI. Cine MRI provided cardiac morphology and function. A quantitative segmentation method was developed to analyze the in vivo T2-maps of hearts at midventricle, apex, and basal regions. The cardiac fibrosis area was analyzed ex vivo by picro sirius red (PSR) staining. Both aged and pressure-overloaded hearts developed significant myocardial contractile dysfunction, cardiac hypertrophy, and interstitial fibrosis. The aged mice had two phenotypes, fibrotic and mild-fibrotic. Notably, the aged fibrotic subgroup and the PO mice showed a marked decrease in T2 relaxation times (25.3 ± 0.6 in aged vs. 29.9 ± 0.7 ms in young mice, p = 0.002; and 24.3 ± 1.7 in PO vs. 28.7 ± 0.7 ms in shams, p = 0.05). However, no significant difference in T2 was detected between the aged mild-fibrotic subgroup and the young mice. Accordingly, an inverse correlation between myocardial fibrosis percentage (FP) and T2 relaxation time was derived (R2 = 0.98): T2 (ms) = 30.45 – 1.05 × FP. Thus, these results demonstrate a statistical agreement between T2-map–quantified fibrosis and PSR staining in two different clinically relevant animal models. In conclusion, T2-mapping MRI is a promising noninvasive contrast agent-free quantitative technique to characterize myocardial fibrosis. 相似文献
3.
4.
目的 运用网络药理学方法及分子对接技术探讨黄芪干预腹膜纤维化的可能机制。方法 利用中药系统药理学数据库及分析平台(TCMSP)检索黄芪的主要化学成分及靶点,并补充文献报道相关药理作用的成分作为潜在活性成分。以"peritoneal fibrosis"为关键词分别在OMIM、Genecards获取目前已知的与腹膜纤维化相关的疾病靶点,后取两者的交集靶点;对交集基因通过STRING数据库与Cytoscape 3.7.2软件构建"药物-成分-靶点-疾病"网络及蛋白互作(PPI)网络并筛选核心网络。基于R软件使用Bioconductor生物信息软件对核心靶点进行GO及KEGG富集分析,最终采用AutoDock软件将主要有效成分与核心靶点进行分子对接,得出其结合能力。结果 筛选出20个黄芪活性成分及文献报道有相关药理作用4个, 457药物作用靶点,与674个腹膜纤维化病靶点取交集,得到86个共同靶点。GO功能富集分析提示黄芪拮抗腹膜纤维化主要参与了蛋白激酶B信号转导的调节、细胞对化学的应激反应、炎症反应的调节等通路; KEGG通路富集分析主要涉及调控肿瘤、磷脂酰肌醇-3-羟激酶-蛋白激酶B(PI3K-Akt)、晚期糖基化终末产物/晚期糖基化终末产物受体(AGE-RAGE)、人类巨细胞病毒感染、HIF-1信号通路等;分子对接结果显示关键靶点与活性成分具有较好的结合能力。结论 黄芪治疗腹膜纤维化的分子机制,可能与抑制炎症及氧化应激反应、调节多种信号通路等相关。 相似文献
5.
6.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
7.
8.
9.
目的 分析新型冠状病毒肺炎(以下简称新冠肺炎)疫情对天津市无偿献血的影响.方法 回顾性分析该市2020年无偿献血人次及献血量,并与2019年献血情况进行对比;分析2020年春节前后及2019年同期的献血情况.结果 2020年捐献全血和单采血小板的总人次较2019年均下降13.03%,献血量分别下降17.60%、10.37%.2020年与2019年春节期间捐献全血和单采血小板的人次和献血量均明显下降,但2020年献血情况持续受疫情影响.2020年1-6月全血和单采血小板的献血情况较2019年同期下降较为明显,2020年7-12月的献血情况好转,与2019年同期差距减小.结论 新冠肺炎疫情对无偿献血工作提出严峻考验.常态化疫情防控期间,分析研判疫情对无偿献血工作的影响,有利于制订更有效的预防措施抗击疫情,保障临床用血. 相似文献
10.